Bristol Myers Squibb · 1 week ago
Vice President, Head of Pharmacovigilance - Safety Science
Maximize your interview chances
BiotechnologyHealth Care
H1B Sponsor Likely
Insider Connection @Bristol Myers Squibb
Get 3x more responses when you reach out via email instead of LinkedIn.
Responsibilities
Develop and lead the global pharmacovigilance strategy to ensure proactive risk management and compliance with local and international PV regulations (e.g., FDA, EMA, ICH).
Oversee end-to-end PV activities, including case processing, safety surveillance, risk management, and signal detection and assessment.
Establish and maintain robust safety governance structures, ensuring alignment with company objectives and industry best practices.
Direct safety evaluation and risk management for clinical and post-marketing products, including benefit-risk assessments, aggregate reporting, and product safety strategy.
Lead the detection, evaluation, and management of safety signals, collaborating with cross-functional teams to implement risk minimization strategies and communicate potential safety concerns.
Oversee safety aspects of regulatory submissions, periodic safety reports (e.g., DSURs, PSURs, RMPs), and responses to regulatory inquiries.
Partner with clinical, regulatory, and medical affairs teams to integrate safety insights into product development, clinical trial design, and labeling strategies.
Act as the key PV representative for interactions with global regulatory authorities and stakeholders, advocating for patient safety.
Engage with external experts, scientific bodies, and industry groups to stay updated on evolving PV practices and enhance the organization's safety profile.
Lead and mentor a high-performing pharmacovigilance and safety science team, fostering a culture of collaboration, accountability, and scientific excellence.
Define and implement processes for continuous improvement within PV operations, safety science, and risk management.
Manage the PV budget, ensuring alignment with organizational priorities and effective use of resources.
Up to 25% travel if not located in San Diego.
Qualification
Find out how your skills align with this job's requirements. If anything seems off, you can easily click on the tags to select or unselect skills to reflect your actual expertise.
Required
MD, PharmD, PhD, or other advanced degree in a relevant field.
15+ years of experience in pharmacovigilance, safety science, or related area within the pharmaceutical/biotechnology industry, with a proven track record of leadership.
Experience in Solid Tumors Oncology is required.
In-depth knowledge of global pharmacovigilance regulations and guidelines, including FDA, EMA, and ICH.
Strong understanding of clinical development, post-marketing safety, and regulatory submissions.
Demonstrated expertise in signal detection, risk management, benefit-risk assessment, and aggregate safety reporting.
Experience interacting with global regulatory authorities and scientific advisory bodies.
Exceptional leadership, strategic thinking, and communication skills.
Preferred
Experience leading a large team within a global organization.
Proven ability to work effectively in a matrixed, cross-functional environment.
Demonstrated commitment to patient safety and ethics in medical practice.
Benefits
Competitive benefits, services and programs
Flexibility in our work environment
Company
Bristol Myers Squibb
At Bristol Myers Squibb, we work every day to transform patients’ lives through science.
H1B Sponsorship
Bristol Myers Squibb has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2023 (152)
2022 (172)
2021 (188)
2020 (188)
Funding
Current Stage
Public CompanyTotal Funding
$23.58BKey Investors
Venrock
2024-02-14Post Ipo Debt· $13B
2023-10-30Post Ipo Debt· $4.5B
2022-02-15Post Ipo Debt· $6B
Recent News
2024-12-09
2024-12-06
Company data provided by crunchbase